Bisphosphonate therapy
For children with osteogenesis imperfecta
Mohamed H. Fadel,MD; Eltayeb M. Nasser,MD; Elsayed M. Ibrahim


Background:
Bisphosphonates are currently the most promising therapy and are commonly used for OI; several studies have been described for symptomatic treatment of OI with bisphosphonates.
This study was performed to assess the outcome of bisphosphonates as a symptomatic treatment of OI.
Patient and method:
A prospective observational study on 16 patients that had been referred to 6 October insurance pediatric orthopedic clinic, all patients were treated and followed from November 2015 to November 2017.
All the cases were moderate form of the disease.
The age range at the start of treatment was 3 to 17 years, the mean age was 6.5.

Result:
All patients' showed improved pain, and activities of daily life greatly during treatment; these were sustained during 2 years follow up. All children became pain free during treatment; no patient was in need of analgesics, except in case of fracture. Decrease of number of fractures per year in all patients up to 50 %, improved deformity in all cases. No side effects were seen during the period of treatment.
Conclusion:
The overall positive results and absence of adverse effects may be sufficient to recommend the use of this treatment for all children with OI who have the severe and moderate forms. So early treatment with bisphosphonates may prevent and decrease skeletal deformity.